NANOSTRING TECHNOLOGIES INC (NSTG)
US63009R1095 - Common Stock
We assign a fundamental rating of 2 out of 10 to NSTG. NSTG was compared to 58 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of NSTG have multiple concerns. While showing a medium growth rate, NSTG is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year NSTG has reported negative net income.
NSTG had a negative operating cash flow in the past year.
In the past 5 years NSTG always reported negative net income.
In the past 5 years NSTG always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -60.59%, NSTG is not doing good in the industry: 91.80% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.59% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-29.8%
ROA(5y)-31.5%
ROE(3y)-149.76%
ROE(5y)-139.62%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NSTG has a worse Gross Margin (35.72%) than 62.30% of its industry peers.
NSTG's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for NSTG so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.22%
GM growth 5Y-7.64%
2. Health
2.1 Basic Checks
NSTG does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NSTG has more shares outstanding
The number of shares outstanding for NSTG has been increased compared to 5 years ago.
NSTG has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -5.51, we must say that NSTG is in the distress zone and has some risk of bankruptcy.
NSTG's Altman-Z score of -5.51 is on the low side compared to the rest of the industry. NSTG is outperformed by 81.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -5.51 |
ROIC/WACCN/A
WACC2.41%
2.3 Liquidity
A Current Ratio of 2.73 indicates that NSTG has no problem at all paying its short term obligations.
NSTG has a Current ratio of 2.73. This is comparable to the rest of the industry: NSTG outperforms 52.46% of its industry peers.
A Quick Ratio of 2.02 indicates that NSTG has no problem at all paying its short term obligations.
NSTG has a Quick ratio of 2.02. This is comparable to the rest of the industry: NSTG outperforms 47.54% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.02 |
3. Growth
3.1 Past
The earnings per share for NSTG have decreased strongly by -12.42% in the last year.
The Revenue has grown by 20.09% in the past year. This is a very strong growth!
NSTG shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.07% yearly.
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q1.27%
Revenue 1Y (TTM)20.09%
Revenue growth 3Y0.45%
Revenue growth 5Y2.07%
Revenue growth Q2Q62.8%
3.2 Future
NSTG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.87% yearly.
Based on estimates for the next years, NSTG will show a very strong growth in Revenue. The Revenue will grow by 22.47% on average per year.
EPS Next Y4.9%
EPS Next 2Y22.45%
EPS Next 3Y18.14%
EPS Next 5Y15.87%
Revenue Next Year40.02%
Revenue Next 2Y26.22%
Revenue Next 3Y23.31%
Revenue Next 5Y22.47%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
NSTG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NSTG. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NSTG's earnings are expected to grow with 18.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.45%
EPS Next 3Y18.14%
5. Dividend
5.1 Amount
No dividends for NSTG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NANOSTRING TECHNOLOGIES INC
NASDAQ:NSTG (2/13/2024, 8:56:56 PM)
After market: 0.1051 0 (-0.19%)0.1053
-0.06 (-37.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap5.07M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -60.59% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 35.72% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.59
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.73 | ||
| Quick Ratio | 2.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y4.9%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)20.09%
Revenue growth 3Y0.45%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y